Arbutus Biopharma Corp (ABUS) vs CeriBell, Inc. (CBLL)

A side-by-side comparison of Arbutus Biopharma Corp and CeriBell, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Arbutus Biopharma Corp logo
ABUS
Arbutus Biopharma Corp
$923M
$4.67HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
CeriBell, Inc. logo
CBLL
CeriBell, Inc.
$943M
$24.86HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ABUS vs CBLL

growth of $100 · dividends reinvested · last 2y
ABUS +23.9% (+11.3%/yr)CBLL -0.6% (-0.3%/yr)ABUS compounded faster over this window
406080100120140Start $10020252026$124$99
ABUS CBLL

ABUS vs CBLL: by the numbers

  • •CBLL is the larger company ($943M vs $923M market cap).
  • •ABUS is profitable (84.23% net margin) while CBLL runs a net loss (-64.73%).

Metrics side by side

Valuation

MetricABUSCBLL
P/E ratio5.98N/A
Forward P/E6.31N/A
P/S ratio5.089.25
P/B ratio3.577.35
EV / EBITDA6.16N/A

Profitability

MetricABUSCBLL
Gross margin99.98%88.90%
Operating margin-192.08%-68.62%
Net margin84.23%-64.73%
ROE59.16%-51.43%
ROIC54.39%-46.54%

Growth (annualized)

MetricABUSCBLL
Revenue CAGR (5Y)85.17%N/A
Total return CAGR (5Y)2.19%N/A

Frequently asked

Is ABUS or CBLL more profitable?
ABUS runs the higher net margin — ABUS at 84.23% versus CBLL at -64.73%.

Go deeper

Full ABUS analysisFull CBLL analysisInteractive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratioArbutus Biopharma ROECeriBell ROEArbutus Biopharma operating marginCeriBell operating marginArbutus Biopharma revenue growthCeriBell revenue growthArbutus Biopharma free cash flowCeriBell free cash flow

Arbutus Biopharma & CeriBell appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.